Correlation Between Cardiac Markers and Severity of COVID-19

NCT ID: NCT05040750

Last Updated: 2024-10-08

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 207 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2021-09-01
• Study Completion Date: 2023-07-30

Brief Summary

By July 9, 2020, the global pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection had resulted in over 11.8 million confirmed cases and over 545000 deaths. Patients with a history of cardiovascular disease are especially vulnerable and have a bad prognosis. According to the findings, cardiac injury manifested by cardiac biomarker elevation is detected in a significant number of COVID-19 patients and is linked to poor outcomes and mortality. However, it is unclear how effective cardiac biomarkers are in COVID-19 prognosis and how to use these indicators.

Detailed Description

The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has led to >11.8 million confirmed cases with >545000 deaths worldwide by July 9, 2020 Patients with preexisting cardiovascular conditions are particularly at risk and have poor prognosis data suggest that cardiac injury, manifested by cardiac biomarker elevation, is detected in a sizable of COVID-19 patients and is associated with adverse outcomes and increased mortality. However, how useful cardiac biomarkers are in COVID-19 prognosis and how to utilize these markers have not been well defined The study will include all moderate to severe COVID 19 patients admitted to ICU. Both genders within the age group 18-60 years were included. The primary outcome is the relation between cardiac markers and mortality rate in critically ill COVID 19 patients The secondary outcome is the relationship between cardiac and inflammatory and coagulation markers

Conditions

Cardiac Event

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Study Groups

moderate to severe COVID 19 patients

moderate to severe COVID 19 patients admitted to ICU. Both genders within the age group 18-60 years were included. Diagnosis of COVID 19 was confirmed

laboratory investigation

Intervention Type: OTHER

observe the relation between cardiac markers and mortality rate in critically ill COVID 19 patients

Interventions

laboratory investigation

observe the relation between cardiac markers and mortality rate in critically ill COVID 19 patients

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• all moderate to severe COVID 19 patients who were admitted to ICU.
• Both genders
• age group 18-60 years

Exclusion Criteria

• a refusal to participate in the study,
• pregnant patients,
• patients aged <18 or >60. years,
• recent history of acute myocardial infarction (< 1 month before admission).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ain Shams University

OTHER

Sponsor Role: lead

Responsible Party

Rania Maher Hussien, MD

Assistant professor of Anaesthesia

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Fathy Tash, MD

Role: STUDY_CHAIR

Ain Shams University

Locations

Ain Shams University

Cairo, , Egypt

Countries

Egypt

Other Identifiers

FMASU R 150 / 2021

Identifier Type: -

Identifier Source: org_study_id